Evidence map›Paper›PMID 41873977›Full record

ArticleHuman vaccines & immunotherapeutics2026

Adverse event following immunization with domestic bivalent human papillomavirus vaccine in Hebei Province, China (2022-2024).

Wang Yihan, Jinghui Wang, Yiqing Zhu, Li Sun, Jing Li, Yafei Wang, Ling Hao, Lina Wang, Di Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wang YihanImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Jinghui WangImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Yiqing ZhuImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Li SunImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Jing LiImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Yafei WangImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Ling HaoImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Lina WangImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.
Di GaoImmunization Planning and Management Institute, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the incidence and characteristics of adverse events following immunization (AEFI) with the domestic bivalent human papilloma virus (HPV) vaccine among females aged 9-45 years in Hebei Province between 2022 and 2024. All vaccination and AEFI data were obtained from the Immunization Information Management System (IIMS) and the National Adverse Event Following Immunization Surveillance System (NAEFISS) in Hebei Province. Descriptive and analytical epidemiological methods were used for statistical analysis. The domestic bivalent HPV vaccine had an AEFI reporting rate of 4.54 per 100,000 doses, comprising common vaccine reactions (3.97/100,000), rare vaccine reactions (0.42/100,000). Significant differences in common vaccine reactions were observed across age groups 9-14 years versus both 15-26 years (

Indexed as

Drug-Related Side Effects and Adverse ReactionsPapillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultAdverse Drug Reaction Reporting SystemsChildChinaFemaleHuman Papillomavirus VirusesHumansIncidenceMiddle AgedVaccinationYoung AdultPapillomavirus Vaccinesadverse event following immunizationbivalent human papilloma virus vaccineDomesticsafetyvaccine

Identifiers

PMID41873977
PMCPMC13014556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.